Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Delayed-Release 6-MP or Calcitriol in Crohn's Disease
NCT00287170Phase 2Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jul 2006
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mercaptopurine and calcitriol in Crohn's disease (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Remission (CDAI < 150) at 12 weeks and Response (CDAI drop >= 100) at 12 weeks. Started Jul 2006; status: completed.
02
Drugs
mercaptopurinecalcitriol
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00287170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00287170.